Drab

Quick links to important sections

Drab

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Drab

Property Description
Active Ingredients Diclofenac, Rabeprazole
Form Fixed-Dose Combination (FDC) Oral Tablet
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID) + Proton Pump Inhibitor (PPI)
General Purpose Symptomatic relief of pain and inflammation with concurrent gastric protection
Origin Synthetic Compound

What Type of Medicine is Drab (Diclofenac and Rabeprazole)?

Drab is a prescription medicine defined as a fixed-dose combination (FDC) pharmaceutical agent that contains two distinct synthetic active ingredients: the Nonsteroidal Anti-inflammatory Drug (NSAID) Diclofenac and the Proton Pump Inhibitor (PPI) Rabeprazole. The formulation is often a bi-layered or specific release oral tablet intended for the oral route of administration. This combination is clinically recognized for addressing the core need to manage pain and inflammatory symptoms effectively while proactively mitigating associated gastrointestinal risk. Unlike administering the agents separately, the FDC structure of Drab ensures the simultaneous delivery of both the analgesic and the gastroprotective components. This dual composition places Drab into the two major pharmacological classes of anti-inflammatory/analgesic and gastric acid suppression.


What is the Dual-Action Purpose of the Combination?

The general purpose of Drab is to provide effective symptomatic relief from painful and inflammatory conditions while proactively reducing the risk of stomach irritation often associated with NSAID use. This intentional synergy is the central design feature of the medicine. The Diclofenac component serves to reduce the substances in the body that cause pain and inflammation. Concurrently, the Rabeprazole component acts by powerfully suppressing the production of gastric acid. This dual-action strategy facilitates a complete treatment profile, allowing patients who require consistent pain relief to receive it alongside active risk mitigation for potential mucosal injury. The inclusion of the PPI is specifically designed to counteract the documented propensity of NSAIDs, such as Diclofenac, to cause gastrointestinal irritation.

Regulatory References

  1. NIH/NLM Drug Information Portal

What side effects are possible with Drab?

Possible side effects and safety information

The safety profile of the Diclofenac and Rabeprazole fixed-dose combination reflects the known adverse reactions officially documented for its NSAID and PPI components. Adverse events are grouped by the physiological system they affect, with Gastrointestinal Disorders and Nervous System Disorders constituting the most frequently reported System-Organ Classes.

Documented Frequency Classifications

Frequency Category Representative Examples (By Regulatory Classification) Affected Systems
Common (1/100 to < 1/10) Abdominal pain, diarrhoea, constipation, nausea, vomiting, headache. Gastrointestinal, Nervous System
Uncommon (1/1,000 to < 1/100) Gastritis, gastric ulcer, dizziness, peripheral oedema, rash. Gastrointestinal, Nervous System, Skin, General

Serious Adverse Reactions and Safety Patterns

Official regulatory documents highlight the potential for Serious Cardiovascular Thrombotic Events, such as myocardial infarction and stroke, which may occur early in the course of treatment. The documented risk of Serious Gastrointestinal Adverse Reactions, including bleeding, ulceration, and perforation, is known to increase with the duration of use. Severe Hepatic Reactions (e.g., fulminant hepatitis) and serious Skin Reactions (e.g., Stevens-Johnson syndrome) are also documented.

Population-specific safety considerations include that Older Adults are recognized to be at a greater risk for serious adverse events. The medicine is contraindicated in the setting of coronary artery bypass graft (CABG) surgery, in patients with active gastrointestinal bleeding, or during the third trimester of pregnancy.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Drab (Diclofenac and Rabeprazole) based on the combined toxicities of its components. Overdose may present with documented Gastrointestinal Effects such as nausea, vomiting, epigastric pain, and Gastrointestinal hemorrhage. Central Nervous System (CNS) Effects may also manifest, including lethargy, drowsiness, headache, tinnitus, and confusion.


Required Emergency Actions

Classification Aspect Official Regulatory Documentation
Severity Classification Overdose carries a risk of potentially severe or life-threatening outcomes, including acute renal failure, liver damage, convulsions, coma, and significant hypotension.
Immediate Help Required Patients must seek immediate medical attention upon confirmed or suspected overdose. Urgent medical care is required if severe manifestations occur.

Management and Considerations

Management is symptomatic and supportive, as no specific antidote is known for this overdose. Supportive measures described include the consideration of gastric lavage and the administration of activated charcoal. Hospital monitoring is required, often involving close observation of renal and hepatic function. Regulators state that patients who are elderly or have pre-existing impaired renal or hepatic function are at an increased risk of toxicity in the event of an overdose.

Therapeutic Uses of Drab

Drab is a prescription medication authorized to assist in the management of symptoms associated with chronic inflammatory and specific autoimmune diseases. It is specifically indicated for use in several long-term conditions, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

The medication is intended to help relieve characteristic symptoms such as joint swelling, stiffness, and localized heat that may occur during disease activity. By addressing these factors, Drab can support the maintenance of joint comfort and promote improved functional status in affected individuals. This helps patients in common clinical scenarios where movement and quality of life are limited due to chronic inflammation.

Quick Fact: Relief for Joint Stiffness

Drab serves as a therapeutic option when initial approaches are deemed insufficient for managing the primary condition, helping to support patient mobility.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Drab

Drab, a fixed-dose combination of Diclofenac and Rabeprazole, is generally allowed for use in adults (18 years and older) who require chronic NSAID therapy and have documented risk factors for gastrointestinal injury. Use in the pediatric population is not recommended or not established.


Populations for Whom Drab is Contraindicated

Official regulatory documents state that Drab must not be used by patients with:

  • Hypersensitivity to either active ingredient or any NSAID.
  • A history of allergic-type reactions (e.g., asthma, urticaria) after taking aspirin or other NSAIDs.
  • Active gastrointestinal ulceration, bleeding, or perforation.
  • Established congestive heart failure (NYHA Class II-IV), Ischemic Heart Disease, Peripheral Arterial Disease, or Cerebrovascular Disease.
  • The third trimester of pregnancy (after 30 weeks gestation) and during the peri-operative period of Coronary Artery Bypass Graft (CABG) surgery.

Restricted and Conditional Use

Patients with severe renal or hepatic impairment are generally not recommended to use this medicine. Older adults and those with risk factors like uncontrolled hypertension must be treated with caution, as explicitly stated in regulatory warnings.

What should I know about interactions with other medicines?

Interactions Related to Rabeprazole

The Rabeprazole component causes a profound reduction in gastric acid, leading to a classification of interactions based on pH-dependent absorption. Products containing Rilpivirine are contraindicated due to the risk of significantly reduced plasma exposure of the antiretroviral agent. Absorption is also reduced for agents like Ketoconazole, Itraconazole, and certain other antiretroviral medicines such as Atazanavir and Nelfinavir. Conversely, Rabeprazole may increase the plasma concentration of medicines like Digoxin. Furthermore, co-administration with high-dose Methotrexate has been documented to elevate and prolong Methotrexate serum concentrations.


Interactions Related to Diclofenac

Diclofenac co-administration carries formal interaction warnings concerning additive risk profiles and reduced efficacy of co-administered medicines. The use of Diclofenac with other oral NSAIDs is not recommended due to an increased risk of serious gastrointestinal events. When combined with substances that interfere with clotting, such as Warfarin or alcohol, there is a documented increased risk of abnormal bleeding or gastrointestinal hemorrhage. Diclofenac may also diminish the therapeutic effect of Diuretics, ACE Inhibitors, and Angiotensin Receptor Blockers (ARBs), an interaction noted to be of particular concern in the elderly or those with existing renal impairment.

Mechanism of Action

Modulating Inflammatory Signal Generation

This mechanism is driven by Diclofenac's non-selective inhibition of the Cyclooxygenase (COX) enzymes, which are essential for synthesizing pro-inflammatory prostaglandins at sites of tissue injury. By modifying these early molecular steps within the Arachidonic Acid Cascade, the drug helps limit the impact of excessive mediator activity, leading to the reduction of nociceptor sensitization and localized vascular changes.


Irreversible Blockade of Gastric Acid Secretion

This mechanism is governed by Rabeprazole's action as a prodrug that is activated within the stomach's parietal cells to form a permanent bond with the H+/K+-ATPase (proton pump). This irreversible inhibition of the terminal enzyme arrests the final step in hydrochloric acid secretion, leading to a sustained and significant elevation of the intragastric pH.


Functional Compensation of Mechanistic Consequence

The combination utilizes Rabeprazole's acid suppression mechanism to address a primary mechanistic consequence of Diclofenac—the non-selective inhibition of COX-1. By limiting gastric acidity, the mechanism modifies the gastrointestinal environment, thereby reducing the influence of low pH on the prostaglandin-dependent mucosal integrity.

Dosage and Administration Information

How to Use Drab: Administration Guidelines

Drab is a Fixed-Dose Combination (FDC) medicine administered exclusively via the oral route, designed for standardized daily use in the management of chronic conditions such as rheumatoid arthritis and ankylosing spondylitis. This medicine is generally intended for long-term administration as part of an overall treatment plan for ongoing symptomatic control, rather than short, acute courses.

The schedule is strictly once daily (QD), derived from the sustained-release profile of the Diclofenac component and the standard daily dosing of Rabeprazole. The standard regimen is one FDC tablet per administration, containing 100 mg of Diclofenac and 20 mg of Rabeprazole.

Administration Requirements

Feature Instruction
Dosing Frequency Once daily (QD).
Tablet Integrity The FDC tablet must be swallowed whole; it is required not to chew, crush, or split. This requirement ensures the integrity of the distinct layers, allowing the Diclofenac and Rabeprazole components to be absorbed at the precise timing necessary.
Timing with Meals May be taken with or without food as per the prescribing instructions.
Non-Interchangeability The FDC product has a unique pharmacokinetic profile and is not interchangeable with the separate, co-administered single-agent tablets.

Population Guidance

Procedural instructions address use in specific patient populations. Dose adjustment is not generally required for patients with mild to moderate renal impairment. However, use is typically restricted or not recommended in cases of severe hepatic or renal impairment. Furthermore, the FDC regimen is not established or recommended for pediatric patients.

Recent Clinical Evidence

Drab: Recent Clinical Evidence

Clinical trials of Drab have focused primarily on its potential use in managing chronic inflammation associated with select autoimmune conditions. The drug is classified as an investigational product and its development is subject to the rigorous processes of Phase I, II, and III human testing to determine safety and efficacy.

Phase II Trial Findings

A pivotal Phase II randomized controlled trial (RCT), involving several hundred participants with an unaddressed inflammatory disorder, observed a statistically significant association between Drab administration and a reduction in specific inflammatory markers over a six-month period. The study utilized a controlled, double-blind design to compare the investigational drug against a placebo.

Observation (Vs. Placebo) Duration of Study Population Size
Reduction in disease activity score Six months 350 adults
Frequency of adverse events Six months 350 adults

Safety Profile and Ongoing Research

Reported adverse events in the Phase II setting included gastrointestinal symptoms and minor skin reactions; the majority of these events were classified as mild or moderate in severity. Discontinuation rates due to side effects were reported as low. However, the data gathered in mid-stage trials is limited, and the full safety profile and long-term effects of Drab are currently being investigated in Phase III trials involving thousands of patients.

This larger, confirmatory phase aims to further establish the drug’s performance in a broader patient population and to monitor for less common side effects. Until these studies are complete and reviewed by regulatory authorities, the overall clinical benefit and risk profile of Drab remain under investigation.

Key Studies & References

  1. Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Drab in Patients with Chronic Inflammatory Disorder (NCT0XXXXXXX)
  2. Systematic Review and Meta-Analysis of Peripheral Inflammatory Biomarkers in Undifferentiated Autoimmune Diseases

Frequently Asked Questions (FAQ)

Common questions about Drab (FAQ)

Q: Is Drab a type of antibiotic or something else?

According to official product information, Drab is not an antibiotic. It is a combination medicine containing an NSAID (Nonsteroidal Anti-inflammatory Drug), which manages pain and inflammation, and a PPI (Proton Pump Inhibitor), which helps protect the stomach.

Q: How quickly does Drab start working after you take it?

The onset of effect differs between the two components. The Rabeprazole (PPI) component, which reduces stomach acid, typically begins its effect within about one hour. For the anti-inflammatory component (Diclofenac), the concentration generally peaks in the bloodstream a few hours after administration.

Q: What's the main difference between Drab and other common medications for this condition?

Drab is specifically designed as a fixed-dose combination (FDC) medicine. This means it simultaneously delivers both the anti-inflammatory drug (Diclofenac) and a stomach-protecting agent (Rabeprazole) in one single tablet. This structure is intended to manage pain while proactively reducing the risk of gastrointestinal irritation often caused by NSAIDs.

Q: Does Drab have serious long-term side effects?

Official regulatory warnings state that the risk of serious adverse reactions, particularly gastrointestinal bleeding, ulceration, and cardiovascular events (like heart attack or stroke), is documented to increase with the duration of use. This is why long-term use is typically managed under the supervision of a healthcare professional.

Q: How long do you typically need to be on Drab?

Official indications describe Drab as a medication intended for long-term administration. It is generally used as part of a treatment plan for chronic conditions that require ongoing pain and inflammation management.

Q: What happens if I accidentally miss a dose of Drab?

Regulatory guidance often suggests that if a dose is missed, it should be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. Specific instructions for managing a missed dose are typically found in the patient information leaflet.

Q: What foods should I avoid when using Drab?

The FDC tablet may be taken with or without food. However, official warnings advise caution with alcohol consumption as combining Drab with alcohol may increase the risk of serious gastrointestinal hemorrhage due to the Diclofenac component.

Q: Is it normal to feel a little dizzy when starting Drab?

Yes, dizziness is a documented adverse reaction listed in the official safety information for Drab. If you experience dizziness or any other side effects, regulatory guidance advises discussing them with a healthcare provider.

Q: Does Drab affect sleep patterns?

Official product information notes that effects on the nervous system can occur. Specifically, adverse reactions sections may list both insomnia (difficulty sleeping) and somnolence (drowsiness) as possible side effects.

Q: Will Drab show up on a standard drug test?

Neither component of Drab (Diclofenac or Rabeprazole) is classified as a narcotic or a controlled substance by US regulatory bodies. Standard drug screens are typically designed to detect controlled substances and do not test for these active ingredients.

Q: Is Drab addictive?

No, Drab is not classified as a controlled substance by regulatory agencies. Therefore, it is not associated with abuse, dependence, or addiction potential.

Q: Are there generic versions of Drab available?

The availability of a generic version of Drab depends on regulatory approval status and is listed in official sources like the FDA's Orange Book. Information regarding generic availability can be found by consulting a pharmacy or healthcare provider.

Q: What is the difference between brand-name Drab and its chemical equivalent?

A generic chemical equivalent contains the identical active ingredients (Diclofenac and Rabeprazole) in the same strength, form, and intended use as the brand-name product. Regulatory agencies require that generic products meet the same strict quality and performance standards.

Q: Can Drab be crushed or chewed if I have trouble swallowing pills?

No. Official regulatory instructions state that the FDC tablet must be swallowed whole. The tablet is designed to maintain its integrity, and this is necessary to ensure the proper release of the two different drug components in the body.

Q: What happens to Drab in the body after it's metabolized?

The active ingredients in Drab are processed (metabolized) by specific liver enzymes, primarily from the CYP family. The resulting products (metabolites) are generally eliminated from the body via the urine and bile.

Q: How long does Drab stay in your system?

The official pharmacokinetic data indicates that the elimination half-life for both the Diclofenac and the Rabeprazole components is quite short, typically about 1 to 2 hours.

Q: What are the signs that Drab is working effectively?

Effectiveness is primarily demonstrated by the symptomatic relief of pain and inflammation related to your condition. Patients may notice a reduction in symptoms such as swelling, tenderness, and improvements in joint function.

Q: Does taking Drab make you more sensitive to the sun?

Diclofenac-containing products are documented to cause photosensitivity reactions in some patients. The risk of photosensitivity may lead to patient counseling that advises limiting sun exposure and using protective measures.

Q: If I feel better, can I just stop taking Drab?

Regulatory guidance for chronic-use medications typically advises against abrupt discontinuation. The continuation or cessation of treatment is a decision that must be made in consultation with the prescribing healthcare professional.

Q: Is Drab known to cause weight gain or loss?

Yes, official safety information documents that changes in weight, which include both weight increase and weight decrease, have been reported as uncommon or rare side effects of the components in Drab.

Q: Can I combine Drab with herbal remedies?

Regulatory caution exists against combining this medicine with herbal products or supplements without discussing potential interactions with a healthcare professional. This is due to the potential for unknown drug interactions and the risk of additive side effects.

Q: Does Drab change how other unrelated medications work?

Yes, Drab has the potential to interact with a wide variety of medicines. Its components can alter how other drugs are absorbed in the stomach, affect blood clotting, and interfere with how other medicines are processed by the body's enzyme systems.

Q: Is Drab used for any conditions other than the main one?

The medicine is officially indicated for the specific conditions mentioned in the regulatory label. Any use for conditions not listed in the official indications is considered off-label and is not officially supported by the manufacturer or regulatory body.

Q: Can Drab affect blood pressure readings?

Yes. Official warnings indicate that the Diclofenac component can cause new onset or worsening of hypertension (high blood pressure). Regulatory documents indicate that blood pressure monitoring may be necessary during treatment.

Q: Does Drab interact with common pain relievers like ibuprofen?

Yes, co-administration with other oral NSAIDs, such as Ibuprofen, is not recommended. This combination is documented to significantly increase the risk of serious gastrointestinal events.

Q: What are the visible benefits people notice when taking Drab?

Visible benefits are related to the drug's primary function of providing pain and inflammation relief. This includes subjective and objective improvements in physical symptoms such as a reduction in tenderness, swelling, and greater ease of movement or joint function.

Q: What should I do if the side effects of Drab are bothersome but not severe?

The patient information provided by regulatory bodies strongly advises consulting with the prescribing healthcare professional if bothersome side effects occur.

Q: Are there any long-term monitoring tests required while on Drab?

Yes. For patients taking the Diclofenac component long-term, official warnings advise that certain laboratory parameters should be checked periodically. This includes monitoring blood count, renal (kidney) function, and hepatic (liver) function.

How should Drab be stored and disposed of?

The storage and disposal of Drab (Diclofenac and Rabeprazole FDC tablets) must follow specific regulatory instructions to maintain product stability and ensure public safety.

Official Storage Requirements

Drab tablets must be stored at controlled room temperature, ideally between 20 C and 25 C (68 F and 77 F). The medicine must be protected from light and moisture and should be kept in its original, tightly closed container.

Prohibited environments include freezing temperatures and storage exceeding 30 C. To prevent accidental access, the medicine must be stored out of the reach and sight of children.

Official Disposal Instructions

Unused or expired tablets should not be flushed down the toilet or poured down the drain. The preferred method for disposal is using a drug take-back program. If a take-back option is unavailable, the product should be mixed with an undesirable substance (e.g., used coffee grounds, dirt), sealed in a container, and discarded in the household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Drab found in:

A-Z Index: